A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Financial Summary
| Share Statistics | IRLA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $28.3 | $224.8 | 12% |
|
| Shares Out (Mil) | 6.1 | 53.9 | 16% |
|
| Institutional Ownership | 49.4% | 93.1% | 23% |
|
| Float (Mil) | 0.7 | 40.6 | 1% |
|
| Beta | 1.26 | 0.95 | 74% |
|
| Avg Daily Volume (000s) | 49 | 632 | 29% |
|
| Price Change (52-week) |
(92.6%) | 47.3% | 4% |
|
| Growth | IRLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (1.8%) | (10.2%) | 38% |
|
| EPS (5yr) | 8.6% | 15.7% | 45 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($1.200) | ($3.653) | ($4.683) | |
| Month Ago EPS | ($1.200) | ($3.653) | ($4.683) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.385) | ($1.480) | ($5.280) | |
| Year/Year Chg | (90.3%) | (98.9%) | (98.7%) | |
| Financials | IRLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($93) | ($44) | 12% |
|
| EPS (TTM) | ($51.805) | ($1.600) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($33) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $99 | $2 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $59 | $174 | 17% |
|
| Valuation | IRLA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IRLA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (76.7%) | (47.7%) | 7% |
|
| ROE | 784.1% | (55.0%) | 100% |
|
| Liabilities to Assets | 12.5% | 29.4% | 8% |
|
| F-Score | 3 | 3 | 18% |
|
IRulya Therapeutics Inc. did not pass any screens on 10/13/2026.
